Search Results - "PENA, Carol"

Characterization and chemo-taxonomic evaluation of plant leaf waxes (long chain n-alkanoic acids, n-alkanes and n-alkanols) as a vegetation biomarker from species of the South American temperate forest (STF) by Cerda-Peña, Carol, Contreras, Sergio

“…[Display omitted] •Knowledge of leaf waxes of South American Temperate Forest plant species is lacking.•Three leaf wax classes on twelve dominant plant species…”
Get full text

Intraspecific differences in leaf chemical traits from five common evergreen species in contrasting climate conditions (temperature and precipitation) from northern Patagonian rainforest (42–44°S) by Cerda-Peña, Carol, Contreras, Sergio, Huguet, A.

“…Background and aims Soil properties and climate influence leaf chemical traits producing intraspecific variation in plants. Studies evaluating their importance…”
Get full text

Effects of trade and poaching pressure on extinction risk for cacti in the Atacama Desert by Villalobo‐Lopez, Angelica, Peña, Carol M., Varas‐Myrik, Antonio, Pillet, Michiel, Jahnsen, Paulina, Pliscoff, Patricio, Goettsch, Bárbara, Guerrero, Pablo C.

“…In this era of a global biodiversity crisis, vascular plants are facing unprecedented extinction rates. We conducted an assessment of the extinction risk of 32…”
Get full text

Molecular phylogeny of the large South American genus Eriosyce (Notocacteae, Cactaceae): Generic delimitation and proposed changes in infrageneric and species ranks by Guerrero, Pablo C., Walter, Helmut E., Arroyo, Mary T.K., Peña, Carol M., Tamburrino, Italo, De Benedictis, Marta, Larridon, Isabel

“…Eriosyce is one of most species-rich genera within Notocacteae (Cactaceae) harboring a variety of stem and flower morphologies, and fruits with basal…”
Get full text

Molecular n-alkyl leaf waxes of three dominant plants from the temperate forest in South America by Cerda-Peña, Carol, Contreras, Sergio, Rau, Jaime R.

“…•In general, no linear relationship between leaf waxes and elevation is observed.•Chusquea sp. n-alkanoic acid abundance is correlated with precipitation and…”
Get full text

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial by PENA, Carol, LATHIA, Chetan, MINGHUA SHAN, ESCUDIER, Bernard, BUKOWSKI, Ronald M

“…Plasma proteins [vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), carbonic anhydrase IX (CAIX), tissue inhibitor of…”
Get full text

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial by Zhu, Andrew X, Kang, Yoon-Koo, Rosmorduc, Olivier, Evans, T R Jeffry, Santoro, Armando, Ross, Paul, Gane, Edward, Vogel, Arndt, Jeffers, Michael, Meinhardt, Gerold, Peña, Carol E A

“…Sorafenib is the current standard therapy for advanced hepatocellular carcinoma, but validated biomarkers predicting clinical outcomes are lacking. This study…”
Get full text

Evaluation of the Foliar Damage That Threatens a Millennial-Age Tree, Araucaria araucana (Molina) K. Koch, Using Leaf Waxes by Gerald Cifuentes, Sergio Contreras, Carol Cerda-Peña

“…A. araucana is an endemic species of the temperate forests from Chile and Argentina; protected in both countries and categorized as in danger of extinction…”
Get full text

An integrative approach to understanding the evolution and diversity of Copiapoa (Cactaceae), a threatened endemic Chilean genus from the Atacama Desert by Larridon, Isabel, Walter, Helmut E., Guerrero, Pablo C., Duarte, Milén, Cisternas, Mauricio A., Hernández, Carol Peña, Bauters, Kenneth, Asselman, Pieter, Goetghebeur, Paul, Samain, Marie-Stéphanie

“…PREMISE OF THE STUDY: Species of the endemic Chilean cactus genus Copiapoa have cylindrical or (sub)globose stems that are solitary or form (large)clusters and…”
Get full text

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors by Vega, Diana Merino, Nishimura, Katherine K, Zariffa, Névine, Thompson, Jeffrey C, Hoering, Antje, Cilento, Vanessa, Rosenthal, Adam, Anagnostou, Valsamo, Baden, Jonathan, Beaver, Julia A, Chaudhuri, Aadel A, Chudova, Darya, Fine, Alexander D, Fiore, Joseph, Hodge, Rachel, Hodgson, Darren, Hunkapiller, Nathan, Klass, Daniel M, Kobie, Julie, Peña, Carol, Pennello, Gene, Peterman, Neil, Philip, Reena, Quinn, Katie J, Raben, David, Rosner, Gary L, Sausen, Mark, Tezcan, Ayse, Xia, Qi, Yi, Jing, Young, Amanda G, Stewart, Mark D, Carpenter, Erica L, Aggarwal, Charu, Allen, Jeff

“…As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies…”
Get more information

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma by LLOVET, Josep M, PENA, Carol E. A, LATHIA, Chetan D, SHAN, Michael, MEINHARDT, Gerold, BRUIX, Jordi

“…Validated biomarkers of prognosis and response to drug have not been identified for patients with hepatocellular carcinoma (HCC). One of the objectives of the…”
Get full text

The importance of wetland habitat area for waterbird species‐richness by Cerda‐Peña, Carol, Rau, Jaime R.

“…The area of habitat patches is a significant factor when determining species‐richness in any given habitat. However, this area effect is not the same for every…”
Get full text

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection by Rudolph, Marion, Anzeneder, Tobias, Schulz, Anke, Beckmann, Georg, Byrne, Annette T., Jeffers, Michael, Pena, Carol, Politz, Oliver, Köchert, Karl, Vonk, Richardus, Reischl, Joachim

Get full text

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma by Dreyling, Martin, Santoro, Armando, Mollica, Luigina, Leppä, Sirpa, Follows, George A, Lenz, Georg, Kim, Won Seog, Nagler, Arnon, Panayiotidis, Panayiotis, Demeter, Judit, Özcan, Muhit, Kosinova, Marina, Bouabdallah, Krimo, Morschhauser, Franck, Stevens, Don A, Trevarthen, David, Giurescu, Marius, Cupit, Lisa, Liu, Li, Köchert, Karl, Seidel, Henrik, Peña, Carol, Yin, Shuxin, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H, Zinzani, Pier Luigi

“…Purpose Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K…”
Get full text

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial by Brose, Marcia S, Dr, Nutting, Christopher M, Prof, Jarzab, Barbara, Prof, Elisei, Rossella, Prof, Siena, Salvatore, MD, Bastholt, Lars, MD, de la Fouchardiere, Christelle, MD, Pacini, Furio, Prof, Paschke, Ralf, Prof, Shong, Young Kee, Prof, Sherman, Steven I, Prof, Smit, Johannes W A, Prof, Chung, John, MD, Kappeler, Christian, PhD, Peña, Carol, PhD, Molnár, István, MD, Schlumberger, Martin J, Prof

“…Summary Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis…”
Get full text

Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial by Brose, Marcia S, Schlumbeger, Martin, Jeffers, Michael, Kappeler, Christian, Meinhardt, Gerold, Peña, Carol E A

“…The phase III DECISION trial (NCT00984282; EudraCT:2009-012007-25) established sorafenib efficacy in locally recurrent or metastatic, progressive,…”
Get full text

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens by Paz-Ares, Luis, Hirsh, Vera, Zhang, Li, de Marinis, Filippo, Yang, James Chih-Hsin, Wakelee, Heather A, Seto, Takashi, Wu, Yi-Long, Novello, Silvia, Juhász, Erszébet, Arén, Osvaldo, Sun, Yan, Schmelter, Thomas, Ong, Teng Jin, Peña, Carol, Smit, Egbert F, Mok, Tony S

“…Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line treatment in patients with non-small-cell lung cancer (NSCLC). The phase III,…”
Get more information

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors by Morschhauser, Franck, Machiels, Jean-Pascal, Salles, Gilles, Rottey, Sylvie, Rule, Simon A J, Cunningham, David, Peyrade, Frederic, Fruchart, Christophe, Arkenau, Hendrik-Tobias, Genvresse, Isabelle, Liu, Li, Köchert, Karl, Shen, Kui, Kneip, Christoph, Peña, Carol E, Grevel, Joachim, Zhang, Jun, Cisternas, Galia, Reschke, Susanne, Granvil, Camille, Awada, Ahmad

“…The PI3K inhibitor copanlisib has efficacy and manageable safety in patients with indolent lymphoma and solid tumors. Pharmacodynamic effects relative to…”
Get full text

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib by Crona, Daniel J, Skol, Andrew D, Leppänen, Veli-Matti, Glubb, Dylan M, Etheridge, Amy S, Hilliard, Eleanor, Peña, Carol E, Peterson, Yuri K, Klauber-DeMore, Nancy, Alitalo, Kari K, Innocenti, Federico

“…Molecular markers of sorafenib efficacy in patients with metastatic renal cell carcinoma (mRCC) are not available. The purpose of this study was to discover…”
Get full text

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma by Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles

“…Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol…”
Get full text